HealthSonix Commences New Clinical Trials to Expand Medical Claims for AquaSonix Therapy
Thursday November 9, 11:30 am ET
IRVINE, CA--(MARKET WIRE)--Nov 9, 2006 -- HealthSonix, Inc. (Other OTC:HSXI.PK - News) (Frankfurt:H7S.F - News) today announced it has commenced a new AquaSonix Therapy clinical trial with patients suffering with pain from osteoarthritis of the knee. The study group has been randomly divided into two groups: one group receives the actual sound pressure wave treatments, while the second control or placebo group, does not.
ADVERTISEMENT
"This clinical study is a Prospective, Randomized, Double-Blind, Single-Centre, Eight Week Trial to Baseline," stated Dr. David Venturi, Medical Director of HealthSonix. "The study will examine pain, function and stiffness levels using the WOMAC questionnaire and life style changes using the SF36 instrument to monitor the patient\'s progress after 5 and 10 and 15 treatment sessions. A physician\'s examination and radiographs have been used to establish the osteoarthritis of the knee diagnosis."
"This study is part of our on-going research efforts to gather more condition-specific scientific evidence for our patent pending sound pressure wave technology, and thereby initiate application of additional medical claims, for disease specific chronic and acute pain conditions," added Dr. Venturi.
AquaSonix Therapy is a breakthrough medical treatment for people with pain, reduced mobility and diminishing flexibility. It\'s a therapeutic water program that combines sound pressure waves with individualized low impact exercises in warm water therapy pools.
HealthSonix, Inc. (Other OTC:HSXI.PK - News) (Frankfurt:H7S.F - News) is a publicly traded medical technology company. The Company\'s core offerings are based on proprietary, patent pending medical technologies that use sound pressure waves to administer sub-sensory micro vibration to the human body. Precisely formatted low frequency sound pressure waves are 80% effective in treating the pain of many diseases, particularly arthritis. All treatments and products are safe, non-invasive, drug free, and have no known side effects.
More information regarding HealthSonix and its products and services can be found at: www.HealthSonix.com or by calling the company at 1-877-622-2121.
Note: A number of statements contained in this report are forward-looking statements, which are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve a number of risks and uncertainties, including the timely development and market acceptance of products and technologies, competitive market conditions, successful integration of acquisitions, the ability to secure additional sources of financing, the ability to reduce operating expenses and other factors not set forth herein. The actual results that the Company may achieve may differ materially from any forward-looking statements due to such risks and uncertainties.
Contact:
Contact:
Dieter D. Doederlein
1-877-622-2121
Email Contact
|
Thread abonnieren
